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Lewis J. Rubin, MDW hile the seminal advance in the treat-ment of pulmonary artery hypertension(PAH) over the past 2 decades has
been pharmacological targeting of dysfunctional
endothelium-derived pathways that contribute to
the characteristic vascular remodeling of this condi-
tion irrespective of etiology (1), several novel in-
terventional techniques have also been useful in
selected patients. Atrial septostomy, which decom-
presses the pressure- and volume-overloaded right
heart and increases left heart ﬁlling and systemic
perfusion, albeit at the expense of arterial oxygen
desaturation (2), has been used in PAH patients with
severe right heart failure refractory to diuretics and
in regions where lung transplantation is not an op-
tion. More recently, balloon angioplasty has shown
promise as a treatment for both inoperable Chronic
Thromboembolic Pulmonary Hypertension (CTEPH)
and for patients in whom the operative risk is deemed
to be unacceptably high (3). In this issue of JACC: Car-
diovascular Interventions, Zhou et al. (4) provide evi-
dence of a pivotal role of the sympathetic nervous
system in the pathogenesis of PAH and demonstrate
that pulmonary artery denervation (PADN) produces
both hemodynamic and structural improvement in
an animal model of PAH.SEE PAGE 2013In dogs with pulmonary hypertension induced by
monocrotaline, Zhou et al. (4) demonstrated that
PADN reduced pulmonary artery pressure and
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pulmonary vascular remodeling. Additionally, mRNA
expression of cytokines and mediators of pulmonary
vasoconstriction and proliferation, which was
increased in dogs in which pulmonary hypertension
developed after monocrotaline injection, was reduced
after PADN. These effects persisted for at least several
months after PADN, suggesting that the procedure
produces a permanent sympathetic denervation of the
pulmonary arterial tree.
One of the most interesting ﬁndings of these ex-
periments is that sympathetic nerve conduction
velocity is markedly abnormal in dogs with mono-
crotaline PAH and that it returns to normal after PADN.
Additionally, the mean nerve conduction velocity in
monocrotaline-treated dogs in which pulmonary
hypertension did not develop was midway between
the means of controls and animals with monocrotaline
PAH, suggesting that in these animals, although
hemodynamically normal, pulmonary vascular abnor-
malities might develop over a more prolonged period
of observation. This cohort deserves further study,
including both a dose-response assessment of exposure
to monocrotaline and a longer period of evaluation.
The importance of the b1-adrenergic system in the
pathogenesis of PAH remains controversial (5).
Studies of b-adrenergic blockers in PAH have been
disappointing, possibly owing to their nonselective
effects (6). Recently, nebivolol, a drug that is a
b1-adrenergic antagonist and a b2,3-adrenergic
agonist, has been demonstrated to produce beneﬁcial
effects in experimental pulmonary hypertension
(7), and Zhou et al. (8) have reported short-term
improvement in an uncontrolled study of PAH pa-
tients treated with PADN. However, long-term
studies are lacking, and these ﬁndings need to be
conﬁrmed by other clinical investigators.
Although the experiments performed by Zhou et al.
(4) are detailed and extensive, the relevance of these
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1) To date, animal models of pulmonary hypertension
have not been predictive of successful therapies
for human disease. In fact, a number of therapies,
including statins and tyrosine kinase inhibitors, can
virtually eliminate pulmonary hypertension in animal
models but have proved to be ineffective or toxic in
PAH patients. 2) Although the predominant histo-
pathological feature in the dogs studied by Zhou et al.
(4) is medial hypertrophy, this is not the typical ﬁnding
in patients with PAH, who have more extensive
vascular changes, including intimal and adventitial
proliferation and plexogenic arteriopathy. Even rats
with monocrotaline-induced pulmonary hypertension
display more advanced vascular lesions, including in-
ﬂammatory changes. 3) It is surprising that heart rate
was unchanged after PADN. I would have expected the
heart rate to slow after PADN, both because of reduced
sympathetic activity and an increased stroke volumeresulting from the reduction in right ventricular
afterload. The reason for this, which may be conse-
quential for PAH patients, is unclear.
Despite these limitations, the report by Zhou et al.
(4) not only provides support for a key role of the
sympathetic nervous system in the pathogenesis of
PAH but also suggests that an intervention designed
to interrupt this sympathetic activation may be a
novel and targeted approach to treatment of this
condition. Although such an approach would be a
welcomed addition to the therapeutic armamen-
tarium for PAH, cautious evaluation in well-designed
clinical trials will be necessary before the utility of
PADN for PAH can be determined.
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